Bloomberg Intelligence cover image

The Fed, ETFs, Supply Chain, and Eli Lilly

Bloomberg Intelligence

00:00

Eli Lilly's Lily Drug Slows Alzheimer's Disease

Lily drug slows Alzheimer's disease. Final stage study shares of Eli Lilly, we're up 6.5% today. We want to get the latest on what that means for Lily and all things pharma. Sam Fezzelli is a pharmaceutical analyst at Bloomberg Intelligence based in London.

Play episode from 44:39
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app